Abstract Number: 645 • ACR/ARHP Annual Meeting 2018
Real World Secukinumab Study in Ankylosing Spondylitis and Psoriatic Arthritis – Comorbidities and Extraarticular Manifestations: Incidence and Status throughout a Non-Interventional Study in Germany
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) may suffer from extraarticular (EA) manifestations (uveitis, psoriasis) and have higher rates of comorbidities like…Abstract Number: 2L • ACR/ARHP Annual Meeting 2017
Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…Abstract Number: 73 • ACR/ARHP Annual Meeting 2017
Regulation of Th17 Cell Responses By IL-25
Background/Purpose: IL-17A is a Th17 proinflammatory cytokine that contributes to the pathophysiology of several immune-mediated inflammatory diseases including PsA; while previously underestimated, there is increasing…Abstract Number: 618 • ACR/ARHP Annual Meeting 2017
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…Abstract Number: 2148 • ACR/ARHP Annual Meeting 2015
Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Background/Purpose: In the Phase 3, randomized, double-blind, placebo (PBO)-controlled, FUTURE 1 study (NCT01392326), the anti–interleukin-17A monoclonal antibody secukinumab provided rapid and significant improvements in key…Abstract Number: 2872 • ACR/ARHP Annual Meeting 2015
Two-Year Clinical Response to Brodalumab, an Anti-Interleukin-17 Receptor Antibody, in Patients with Psoriatic Arthritis
Background/Purpose: The interleukin-17 (IL-17) cytokine family plays a key role in the pathogenesis of psoriatic diseases of skin and joint. Brodalumab is a fully human…Abstract Number: 1557 • ACR/ARHP Annual Meeting 2014
Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Background/Purpose: Interleukin-17 (IL-17) plays a role in the pathogenesis of psoriatic disease of both skin and joint. We sought to assess long-term efficacy and safety…Abstract Number: 2487 • ACR/ARHP Annual Meeting 2013
Role Of IL-33 In The Development Of Premature Atherosclerosis In Psoriatic Arthritis Patients
Background/Purpose: Interleukin 33 (IL-33) is a newly identified member of the IL-1 cytokine family. It involves in T-cell mediated immune responses through the activation of…Abstract Number: 817 • ACR/ARHP Annual Meeting 2013
Clinical Response To Brodalumab, An Anti-Interleukin-17 Receptor Antibody, In Subjects With Psoriatic Arthritis
Background/Purpose: Psoriasis-associated skin and joint disorders are characterized by ongoing inflammation mediated by similar molecular pathways. IL-17 plays a potential role in the pathogenesis and…Abstract Number: L7 • ACR/ARHP Annual Meeting 2013
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture Study
Background/Purpose: Secukinumab (SEC; AIN457), a fully human anti–IL-17A monoclonal antibody, has demonstrated efficacy in phase 3 trials for treatment of plaque psoriasis and preliminary results…
ACR Meeting Abstracts